MADISON, N.J., July 14 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE)
announced today that Judge Jamie D. Happas of the New Jersey Superior Court
in New Brunswick has granted Wyeth's motion for summary judgment in two
hormone therapy cases that were scheduled for trial later this year. The
court dismissed the cases of Bailey v. Wyeth, which was to have begun on
September 15, and DeBoard v. Wyeth, which had an October 27 trial date. The
plaintiffs in both cases alleged they developed breast cancer as a result
of the use of Prempro(TM) and Premarin(R), hormone therapy products
marketed by Wyeth, as well as Provera(R), a progestin product marketed by
Upjohn.
In granting the motions, Judge Happas ruled, among other things, that
the plaintiffs "failed to provide the specific type of evidence necessary
to overcome the presumption of adequacy afforded [to] FDA-approved
labeling" by New Jersey law and that the warnings were "adequate as a
matter of law."
"We believe the court's ruling was a proper application of New Jersey
law and is consistent with a growing body of law around the nation,
rejecting challenges to FDA-approved labeling," says Lauren E. Handler, a
partner with Porzio Bromberg & Newman, P.C., a New Jersey-based firm
representing Wyeth in both cases.
About Wyeth
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery,
development, manufacturing and marketing of pharmaceuticals, vaccines,
biotechnology products, nutritionals and non-prescription medicines that
improve the quality of life for people worldwide. The Company's major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort
Dodge Animal Health.
SOURCE Wyeth
 back to top
Related links:
http://www.wyeth.com
CONTACT:
Media, Douglas Petkus, +1-973-660-5218, or
Investor, Justin Victoria, +1-973-660-5340, both of Wyeth
|
